/SNY
Sanofi
SNY • NASDAQSNY • NASDAQ • Healthcare
$46.22-0.54%-0.25
$46.22-0.54%(-0.25)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
92Bullish
Risk
100Low Risk
Momentum
38Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
72.3%▲2.2pp
Revenue after COGS
Operating
13.6%▼2.8pp
After operating expenses
Net
16.7%▲4.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
12.9
Price vs earnings
EV/EBITDA
9.1
Enterprise value
FCF Yield
8.8%
Cash generation
Earnings Yield
7.8%
Inverse of P/E
Capital Efficiency
7
GoAI Quality ScoreWeak
ROEReturn on Equity
10.9%Fair
ROAReturn on Assets
6.2%Strong
ROICReturn on Invested Capital
5.1%Fair
Financial Health
Current RatioAdequate
1.09
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
1.11x
Debt repayment capacity (<3x)
Income QualityStrong
1.38
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $46.72B | $44.29B | $41.62B | $40.56B | $39.17B |
| Gross Profit | $33.79B | $31.08B | $28.99B | $28.68B | $26.92B |
| Gross Margin | 72.3% | 70.2% | 69.7% | 70.7% | 68.7% |
| Operating Income | $6.34B | $7.25B | $6.96B | $10.16B | $8.13B |
| Net Income | $7.81B | $5.56B | $5.40B | $8.37B | $6.22B |
| Net Margin | 16.7% | 12.6% | 13.0% | 20.6% | 15.9% |
| EPS | $2.03 | $2.19 | $2.15 | $3.19 | $2.49 |
Average Price Target
$57.02▲ 23.4% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Sanofi, the average price target is $57.02, with a high forecast of $64.00 and a low forecast of $48.07. The average price target represents a 23.4% increase from the current price of $46.22.
Highest
$64.00
Average
$57.02
Lowest
$48.07
Rating Distribution
Strong Buy
0
0%
Buy
14
52%
Hold
11
41%
Sell
2
7%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
UBS▼ Downgrade
Buy→Neutral
2026-01-16Barclays▼ Downgrade
Overweight→Equal Weight
2026-01-06Guggenheim▼ Downgrade
Buy→Neutral
2025-12-09JP Morgan▼ Downgrade
Overweight→Neutral
2025-12-08Morgan Stanley▲ Upgrade
Equal Weight→Overweight
2025-09-08Deutsche Bank▲ Upgrade
Hold→Buy
2025-09-02JP Morgan▲ Upgrade
Neutral→Overweight
2025-08-08Argus Research● Maintain
Buy
2024-07-26Argus Research● Maintain
Buy
2023-03-27Argus Research● Maintain
Buy
2023-03-26Earnings History & Surprises
BEAT RATE
72%
Last 18 quarters
AVG SURPRISE
+2.5%
EPS vs Estimate
BEATS / MISSES
13/5
Last 18 quarters
LATEST EPS
$0.89
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+6.0%
$0.89 vs $0.84
Q4 '25
+6.2%
$1.70 vs $1.60
Q3 '25
-6.2%
$0.90 vs $0.96
Q2 '25
+4.4%
$0.94 vs $0.90
Q1 '25
-1.4%
$0.70 vs $0.71
Q4 '24
+16.3%
$1.57 vs $1.35
Q3 '24
+8.1%
$0.93 vs $0.86
Q2 '24
+3.2%
$0.97 vs $0.94
Q1 '24
-5.3%
$0.89 vs $0.94
Q4 '23
+1.5%
$1.39 vs $1.37
Q3 '23
-38.7%
$0.95 vs $1.55
Q2 '23
+5.5%
$1.16 vs $1.10
No investor questions available.
Latest News
No news available